BLOOD PRESSURE WINS: THE CARDIOVASCULAR NUMBERS MEN SEE BY MONTH 6

Updated July 18, 2026

The weight loss headlines dominate GLP-1 coverage. But for men over 35 with hypertension — and that is roughly one in three American men — the blood pressure improvements may be the single most valuable clinical outcome of treatment. By month 6, the numbers many men see on their home monitors are genuinely surprising.

WHAT THE TRIALS SHOWED

Across the STEP and SURMOUNT clinical trials, GLP-1 receptor agonists produced consistent blood pressure reductions. Semaglutide reduced systolic BP by an average of 4.7 to 6.2 mmHg and diastolic BP by 1.6 to 2.8 mmHg. Tirzepatide showed slightly larger reductions: 6 to 8 mmHg systolic and 3 to 4 mmHg diastolic. These are population averages — individual responses range from negligible to dramatic (20+ mmHg systolic reduction in some patients).

To put these numbers in context: a 5 mmHg sustained reduction in systolic blood pressure reduces stroke risk by approximately 14% and coronary heart disease risk by 9%. For men in the hypertensive range (systolic above 130), this single effect of GLP-1 treatment may deliver more life-years than the weight loss itself.

HOW IT HAPPENS

GLP-1-mediated blood pressure improvement comes from multiple pathways:

Weight loss. Every 2.2 pounds (1 kg) of weight lost produces approximately 1 mmHg reduction in systolic blood pressure. A man who loses 30 pounds can expect roughly 14 mmHg of systolic reduction from weight loss alone — potentially enough to move from Stage 1 hypertension to normal.

Reduced sodium retention. GLP-1 receptor agonists increase natriuresis (sodium excretion through the kidneys). Less sodium retention means less fluid volume, which directly lowers blood pressure. This effect is independent of weight loss and partially explains why BP improvements sometimes precede significant weight change.

Vascular function improvement. Emerging evidence suggests GLP-1 medications improve endothelial function (the ability of blood vessels to dilate properly). Better endothelial function means lower peripheral resistance, which reduces blood pressure mechanically.

Reduced visceral fat. Visceral fat produces inflammatory cytokines that stiffen arteries and increase vascular resistance. As GLP-1s preferentially reduce visceral fat (discussed in our belly fat article), the inflammatory load decreases and arterial compliance improves.

THE MONTH-6 CHECKPOINT

Month 6 is when blood pressure improvements typically plateau — most of the weight-mediated BP reduction has occurred, and the direct pharmacological effects have fully manifested. This is the right time for a comprehensive cardiovascular assessment:

Check average home BP over 2 weeks. Take readings morning and evening, same arm, seated, 5 minutes of rest before measurement. Average 14 days of readings. This is more accurate than a single office visit measurement.

Compare to pre-treatment baseline. If you took your blood pressure before starting the GLP-1 (and if you didn't, start now for future reference), the difference tells you the magnitude of your treatment response.

Discuss medication adjustment with your PCP. If your average home systolic is below 120 and you are on antihypertensives, you may be overmedicated. Symptoms of overtreatment include dizziness on standing, lightheadedness, and fatigue — which can be confused with GLP-1 side effects.

Get a lipid panel. GLP-1 medications also improve lipid profiles (reduced triglycerides, modest LDL reduction, HDL improvement). Combined with blood pressure data, the full cardiovascular picture at month 6 is often dramatically improved from baseline.

Sources: STEP trial cardiovascular outcome data; SURMOUNT trial blood pressure analysis; AHA/ACC blood pressure guidelines; relationship between weight loss and blood pressure in meta-analytic reviews. This article does not constitute medical advice. Blood pressure medication adjustments require physician oversight.